



## **Vyvanse® (lisdexamfetamine dimesilate) Now PBS listed for Australian Adult Patients with ADHD**

*From 1 February 2021 Vyvanse® (lisdexamfetamine dimesilate) will be the first long-acting stimulant to be listed on the Pharmaceutical Benefits Scheme (PBS) for Australians with Attention Deficit Hyperactivity Disorder (ADHD) who are diagnosed after the age of 18.<sup>1,2</sup>*

Takeda Pharmaceuticals is pleased to announce this change that will improve patient access to its long-acting therapy. The Pharmaceutical Benefits Advisory Committee (PBAC) reimbursement submission was supported by over 200 comments from individuals, healthcare professionals and patient organisations.<sup>3</sup>

Yours Sincerely

Ben Hopkins

Neuroscience Franchise Director

### References:

<sup>1</sup> Vyvanse (lisdexamfetamine) Product Information. Available at: <http://www.guildlink.com.au/gc/ws/tk/pi.cfm?product=tkpvyvan10420> (Date accessed: December 2020)

<sup>2</sup> Pharmaceutical Benefits Advisory Committee (PBAC). Public Summary Document (PSD) March 2020 PBAC Meeting. Available from: <https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2020-03/files/lisdexamfetamine-psd-march-2020.pdf> (Accessed December 2020)

<sup>3</sup> VYVANSE Public Summary Document – July 2019 PBAC Meeting. Accessed from <https://www.pbs.gov.au/pbac-meetings/psd/files>

Takeda Pharmaceuticals Australia Pty Ltd, Sydney, NSW 2000. Tel: 1800 012 612.  
Email: [medinfoAPAC@takeda.com](mailto:medinfoAPAC@takeda.com) ABN 71 095 610 870.  
VYVANSE® and the VYVANSE Logo® are registered trademarks of  
Takeda Pharmaceuticals U.S.A., Inc. TAKEDA® and the TAKEDA Logo® are  
registered trademarks of Takeda Pharmaceutical Company Limited.  
Date of Preparation Jan 2021. C-ANPROM/AU/Vyv/0005



## Frequently Asked Questions

- 1. If a patient is currently prescribed Vyvanse and meets the new PBS eligibility criteria for adults diagnosed with ADHD after the age of 18, will they need to see their doctor to obtain a new PBS prescription (to replace their current private Vyvanse prescription)?**

Yes. A patient who meets the new Vyvanse Adult PBS eligibility criteria will need their specialist to provide a new PBS prescription which should include the appropriate PBS authority number.

- 2. Will all strengths of Vyvanse be PBS listed for the reimbursement?**

Yes. As of February 1<sup>st</sup> 2021 all strengths of Vyvanse will be PBS listed for adults who meet the PBS eligibility criteria for adults diagnosed with ADHD after the age of 18.

- 3. How much are patients required to pay now that Vyvanse is PBS listed?**

Vyvanse is now covered under the PBS, however, patients will have to pay a co-payment expected with every reimbursed medication. According to the following PBS website <https://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee> last updated 1 January 2021, the copayments are listed as:

General patient copayment - \$41.30

Concessional patient copayment - \$6.60

Link to Vyvanse Consumer Medicine Information: <http://www.guildlink.com.au/gc/ws/tk/cmi.cfm?product=tkcvyvan10118>

PBS Information: **AUTHORITY REQUIRED.** Attention deficit hyperactivity disorder (ADHD).

Refer to PBS Schedule for full authority information.

### **Minimum Product Information. VYVANSE® (lisdexamfetamine dimesilate).**

**For further information about the appropriate selection of patients and prescribing of VYVANSE, please visit <http://www.idxguide.com/au> (password: onetakeda)**

VYVANSE has a potential for abuse, misuse, dependence, or diversion for non-therapeutic uses. Physicians should assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy. VYVANSE should be prescribed cautiously to patients with a history of substance abuse or dependence. Careful supervision is required during withdrawal from abusive use since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.

Takeda Pharmaceuticals Australia Pty Ltd, Sydney, NSW 2000. Tel: 1800 012 612.

Email: [medinfoAPAC@takeda.com](mailto:medinfoAPAC@takeda.com) ABN 71 095 610 870.

VYVANSE® and the VYVANSE Logo® are registered trademarks of Takeda Pharmaceuticals U.S.A., Inc. TAKEDA® and the TAKEDA Logo® are registered trademarks of Takeda Pharmaceutical Company Limited.

Date of Preparation Jan 2021. C-ANPROM/AU/Vyv/0005



**Indication:** Attention Deficit Hyperactivity Disorder (ADHD): Indicated for treatment of ADHD. Treatment should be commenced by a specialist as part of a comprehensive treatment program and re-evaluated periodically during long-term use.

Binge Eating Disorder (BED): Indicated for treatment of moderate to severe BED in adults when non-pharmacological treatment is unsuccessful or unavailable. Treatment should be commenced and managed by a psychiatrist.

**Dosage and Administration:** VYVANSE should be initiated at 30 mg once daily in the morning (avoid afternoon doses due to potential for insomnia) and slowly adjusted to the lowest effective dose (no more frequently than weekly). Capsules may be taken whole, or opened and the contents emptied and mixed with a soft food such as yogurt or in a glass of water or orange juice.

**Contraindications:** Advanced arteriosclerosis; symptomatic cardiovascular disease (eg cardiac arrhythmia, ischaemic heart disease); moderate to severe hypertension; hyperthyroidism; hypersensitivity or idiosyncratic reaction to sympathomimetic amines or any of the excipients; glaucoma; agitated states (eg severe anxiety, tension and agitation); administration during or within 14 days of cessation of MAOIs; pheochromocytoma; tics, Tourette's syndrome; patients who exhibit severe depression, anorexia nervosa, psychotic symptoms or suicidal tendency; drug dependence or alcohol abuse.

**Precautions:** Cardiovascular disease; psychiatric disorders (psychosis, bipolar disease, aggression); seizures; visual disturbance; long-term suppression of growth, peripheral vasculopathy including Raynaud's phenomenon. Renal impairment (severe renal insufficiency max dose 50mg/day; dose reduction for dialysis patients). No data in hepatic impairment. Pregnancy: Category B3. Women taking VYVANSE should refrain from breast feeding. Not studied in children <6 years or adults >55 years of age.

**Interactions:** MAOIs (see Contraindications), antihypertensives, narcotic analgesics, antipsychotics, agents that alter urinary pH, serotonergic drugs.

**Adverse Effects:** Very Common reactions: decreased appetite, insomnia, headache, dry mouth, upper abdominal pain, weight decreased. Common reactions: anorexia, agitation, anxiety, libido decreased, tic, affect lability, psychomotor hyperactivity, bruxism, aggression, dizziness, restlessness, tremor, somnolence, mydriasis, tachycardia, palpitation, dyspnoea, diarrhoea, nausea, vomiting, hyperhidrosis, rash, irritability, fatigue, feeling jittery, pyrexia, blood pressure increased, erectile dysfunction. Note: where frequency of adverse reactions varies across age groups (children, adolescents, adults), the adverse reaction is listed according to the highest frequency.

(pi-01047. V1.0)